22 results about "Polysorbates" patented technology

The invention discloses a self-emulsifying adjuvant of a vaccine and a preparation method of the self-emulsifying adjuvant, and relates to the technical field of vaccine adjuvants. The adjuvant comprises an oil phase, an emulsifier and a freeze-drying protective agent, the oil phase comprises squalene and tocopherol, the emulsifier comprises polysorbate and a polyoxyethylene-polyoxypropylene block copolymer, and the freeze-drying protective agent comprises sugar and sugar alcohol. The preparation method comprises the following steps: emulsifying an oil phase and a water phase to form a nano-emulsion, and then freeze-drying to obtain freeze-dried powder. The adjuvant has the advantages of small particle size, uniform distribution, high stability, rapid reconstruction and the like, and can effectively maintain active components and improve the immune effect of vaccines.

A noninvasive ophthalmic formulation, comprising a chelator (such as EDTA and its salts), a transport enhancer (such as Methyl Sulfonyl Methane; MSM), a second permeation enhancer such as propylene glycol, a thickening agent such as hydroxyethyl cellulose (HEC) and a surfactant such as polysorbate 80, is provided. The novel combination of the ingredients unexpectedly and beneficially reduces symptoms associated with early-stage, age-related cataracts. Methods for treating cataracts with compositions of the invention and measurement of improved visual function by measuring contrast sensitivity (CS) are provided.

The invention discloses epichlorohydrin and a preparation method thereof. Comprising the following steps: feeding a mixed solution containing chloropropene, hydrogen peroxide and a nonionic surfactant and a titanium silicalite molecular sieve TS-1 catalyst in a fixed bed reactor at a mass space velocity of 0.5-10h <-1 >, and reacting at 20-90 DEG C to obtain the epichlorohydrin. The dosage of the catalyst is 0.1-10 wt% of the chloropropene; the nonionic surfactant is selected from at least one of alkyl glucoside, fatty glyceride, fatty acid sorbitan, polysorbate, polyoxyethylene fatty alcohol ether and nonylphenol polyoxyethylene ether; the molar ratio of the hydrogen peroxide to the nonionic surfactant is (1-50): 1; the molar ratio of chloropropene to hydrogen peroxide is (1-10): 1. The nonionic surfactant is added to promote mixing of the organic phase and the water phase, a large amount of solvent does not need to be added in a traditional process, and a large amount of energy consumption such as solvent evaporation and recovery is avoided; the conversion rate of hydrogen peroxide is greater than 95%, and the selectivity of epoxy chloropropane is 95-99%.

An adhesive composition is described herein. More particularly, an adhesive composition with a hydrophilic adhesive, a hydrophobic adhesive, at least one surfactant, and at least one plasticizer. Specifically, the adhesive is a blend of a continuous phase hydrophilic adhesive, a dispersed phase hydrophobic adhesive, at least one surfactant, at least one plasticizer selected from the group consisting of fatty alcohol ethoxylates, tristyrylphenol ethoxylates, alkyl ether sulfates, sulfosuccinate esters, polysorbates, glycerides and combinations thereof and wherein a weight ratio of the hydrophilic adhesive to the plasticizer is between about 1:4 and about 4:1.

The invention relates to the technical field of pharmaceutics, in particular to a monoclonal antibody preparation for inhibiting fibrosis after an eye operation and application. The anti-periostin humanized monoclonal antibody injection preparation provided by the invention is prepared from the following components: an anti-periostin humanized monoclonal antibody, a buffering agent, amino acid, polysorbate and trehalose. The preparation is stable in property. The biological activity is good, and the stimulation to eyeballs can be reduced.

Provided are a lyophilized buagafuran flashtab and a method for preparing same. The provided lyophilized buagafuran flashtab comprises the following raw materials in percentage by mass: 10%-90% of a buagafuran-mEV substance solution, 1%-5% of a binder, 0.1%-2% of a suspending agent, 0.1%-1% of a surfactant, 0.1%-1% of a sweetener, 0.1%-1% of a flavoring agent, and the balance of water. The surfactant is selected from polysorbate 80. The buagafuran is one or more of buagafuran and in-vivo metabolites thereof. Also provided is a method for preparing the lyophilized buagafuran flashtab. The lyophilized flashtab is prepared by lyophilization technology, thus possessing good stability, dissolution performance, and desirability for the oral absorption of buagafuran. Furthermore, the method features simplification and ease to implement.

The invention discloses a plastic deinking agent and a preparation method and application thereof, and belongs to the technical field of deinking agents. The plastic deinking agent is composed of an organic solvent, a surfactant and water; the organic solvent is composed of an ether solvent, an ester solvent, a ketone solvent and an amide solvent; the surface active agent is prepared from a polysorbate surface active agent and a polyoxyethylene surface active agent. The plastic deinking agent provided by the invention has the effects of emulsifying, wetting, dispersing and stripping printing ink on plastic, can effectively destroy the adhesive force of the printing ink on the plastic, and can recycle the printing ink on a plastic cup or clean dirt on the printing ink, and the stripped printing ink cannot be deposited on the plastic cup. The plastic deinking agent disclosed by the invention has the characteristics of low foam, easiness in cleaning, recyclability and high cost performance.

The present invention relates to the field of pharmacy and medicine, i.e. To compositions of quick-acting, injectable insulin formulations. More specifically, the present invention relates to a composition comprising insulin aspart, a nicotinic acid compound, a surfactant selected from poloxamer 188, polysorbate 20, polysorbate 80, or a combination thereof, and an amino acid selected from lysine, arginine, and / or a salt thereof, and / or a combination thereof. The compositions of the present invention are useful for reducing blood glucose levels in subjects, particularly suitable for insulin formulations requiring high stability against thermal and / or physical and mechanical stresses.

The present invention provides a stable high-concentration anti-PD-1 antibody pharmaceutical formulation, which comprises an anti-PD-1 antibody, histidine-histidine hydrochloric acid, proline, methionine, polysorbate 20 or polysorbate 80, and optional arginine or arginine hydrochloric acid, with a pH value of 5.0-6.0. The present invention further provides use of the anti-PD-1 antibody pharmaceutical formulation in preparing a drug for treating cancers.

The present invention is directed to methods for treating or preventing neuroinflammation in a subject by administering an effective amount of a single-domain antibody (sdAb) comprising SEQ ID NO:1. The method is applicable to subjects with multiple sclerosis, including secondary progressive, primary progressive, and relapsing-remitting forms. Administration may be intravenous, subcutaneous, or intrathecal, with dosage regimens including daily administration, loading and maintenance doses, or continuous infusion. The method may be initiated upon first clinical signs of central nervous system demyelination and continued for at least 14 days. The sdAb may be co-administered with a pharmaceutically acceptable excipient such as mannitol, sucrose, or polysorbate 80, and optionally combined with disease-modifying therapies including interferon-β, glatiramer acetate, fingolimod, or ocrelizumab. The invention provides a targeted approach for modulating neuroinflammatory processes in neurological disorders.

The invention discloses epichlorohydrin and a preparation method thereof. Comprising the following step: reacting a mixed solution containing chloropropene, hydrogen peroxide and a nonionic surfactant with a titanium silicalite molecular sieve TS-1 catalyst in a continuous reactor at the liquid phase flow velocity of 0.1-20L / min and the reaction temperature of 20-90 DEG C to obtain the epichlorohydrin. The nonionic surfactant is selected from at least one of alkyl glucoside, fatty glyceride, fatty acid sorbitan, polysorbate, polyoxyethylene fatty alcohol ether and nonylphenol polyoxyethylene ether; the molar ratio of the hydrogen peroxide to the nonionic surfactant is (1-50): 1; the molar ratio of chloropropene to hydrogen peroxide is (1-10): 1. The nonionic surfactant is added to promote mixing of the organic phase and the water phase, a large amount of solvent does not need to be added in a traditional process, a large amount of energy consumption such as solvent evaporation and recovery is avoided, and continuous operation is achieved; the conversion rate of hydrogen peroxide is greater than 95%, and the selectivity of epoxy chloropropane is 95-99%.

An adhesive composition is described herein. More particularly, an adhesive composition with a hydrophilic adhesive, a hydrophobic adhesive, at least one surfactant, and at least one plasticizer. Specifically, the adhesive is a blend of a continuous phase hydrophilic adhesive, a dispersed phase hydrophobic adhesive, at least one surfactant, at least one plasticizer selected from the group consisting of fatty alcohol ethoxylates, tristyrylphenol ethoxylates, alkyl ether sulfates, sulfosuccinate esters, polysorbates, glycerides and combinations thereof and wherein a weight ratio of the hydrophilic adhesive to the plasticizer is between about 1:4 and about 4:1.

The invention relates to the technical field of pharmaceutical preparations, in particular to an ipratropium bromide solution for inhalation and a preparation method of the ipratropium bromide solution. The preparation method of the ipratropium bromide solution for inhalation comprises the following steps: dissolving sodium chloride in water for injection, regulating the pH value to 3.1-3.5 by adopting a citric acid-sodium citrate buffer system, then adding a composite surfactant, finally adding ipratropium bromide, stirring, dissolving, fixing the volume, filtering and sterilizing, thereby obtaining the ipratropium bromide solution for inhalation. The composite surfactant is a mixture of polysorbate 20, polysorbate 60 and polysorbate 80. The ipratropium bromide solution for inhalation has excellent stability, can be stored for a long time without deterioration, has relatively excellent atomization performance, and can meet the requirements of various patients.

The invention relates to the technical field of biological medicines, in particular to an IgG4 monoclonal antibody pharmaceutical preparation as well as a preparation method and application thereof. The invention provides an IgG4 monoclonal antibody pharmaceutical preparation. The IgG4 monoclonal antibody pharmaceutical preparation comprises an IgG4 monoclonal antibody, poloxamer 188 and a pharmaceutically acceptable buffer solution. The research system evaluates the feasibility of replacing the traditional polysorbate by the poloxamer 188 for stabilizing the IgG4 monoclonal antibody. By combining thermodynamic analysis, interfacial property determination and multi-stress model experiments, the stress dependency difference of a surfactant stabilization mechanism is researched and revealed, and an important theoretical basis is provided for reasonable selection of a stabilizer in a protein preparation.

The invention provides a perfluorohexanone stable emulsion based on a microchannel and a preparation method thereof, and belongs to the technical field of fire extinguishing agent preparation. The perfluorohexanone stable emulsion is in an oil-in-water type, an outer water phase wraps an oil phase, the oil phase is a perfluorohexanone phase, and the preparation and regulation of the perfluorohexanone stable emulsion are realized by adjusting the injection pump rates of the water phase and the perfluorohexanone phase; and the water phase comprises the following components: a polysorbate surfactant, alkylphenol polyoxyethylene ether, polyvinyl alcohol, deionized water and glycerol. The stable perfluorohexanone emulsion prepared by the invention continuously absorbs heat when being in contact with a combustible material, and effective cooling is finally realized. When the environment temperature rises, the water and the perfluorohexanone are vaporized and expanded, the expanded water vapor and perfluorohexanone steam occupy a combustion area and weaken air supply, the local oxygen volume fraction is reduced, and therefore the combustion intensity is reduced, and finally fire extinguishing is achieved.

The present invention discloses a rhodomyrtone inhalation suspension and a preparation method thereof. The rhodomyrtone inhalation suspension is obtained by mixing the following raw materials and auxiliary materials in percentage by weight: rhodomyrtone 0.02%-1%, surfactant 0.005%-0.1%, suspending agent 0-2.2%, pH regulator 0.01%-0.03%, flocculant 0.02%-0.04%, stabilizer 0.005%-0.015%, osmotic pressure regulator 0.7%-1.1%, and water as the balance; the surfactant is polysorbate; and the suspending agent is povidone K30 and / or microcrystalline cellulose-sodium carboxymethylcellulose. The inhalation suspension has a high effective lung deposition rate and accurate delivery dose, and can accurately deliver a set dose of rhodomyrtone directly to lung lesions, exerting its antiviral efficacy.

The invention discloses a blending method for adjusting skin disease plaster according to humidity, and belongs to the technical field of plaster compositions.The method comprises the steps that under the preset temperature and humidity, polyethylene glycol is added into a mixture containing multiple matrixes in batches, a pre-prepared mixture of hydroxypropyl methyl cellulose and carbomer is added in three times, and the mixture is stirred to be uniform; performing variable-speed stirring to a transparent gel state; and slowly adding a mixture of polysorbate and polyoxyethylene sorbitan monooleate which are heated to a preset temperature into the colloidal mixture under the condition of controlling the temperature difference, and adding a trehalose aqueous solution for stirring to obtain the target paste. Through the scheme of the invention, the expansion degree fluctuation of the paste with different humidity can be reduced, and the stability is improved.

The invention discloses a methylprednisolone acetate injection for inhibiting inflammation and a preparation method thereof, and relates to the technical field of medicine preparation, each milliliter of the methylprednisolone acetate injection comprises 45mg of methylprednisolone acetate, 2mg of mixed medicament, 15mg of surfactant, 15mg of cosurfactant and 5mg of solubilizer, the mixed medicament comprises 20mg of povidone and 15mg of polyethylene glycol, and the surfactant comprises 5mg of cosurfactant and 5mg of solubilizer. The preparation method comprises the following steps: adjusting the raw materials to be isotonic by using a sodium chloride solution, adjusting the pH value to be 4.5-7.0 by using sodium hydroxide and the balance of water, wherein the raw materials comprise 2mg of sodium carboxymethyl cellulose, 1.5 mg of polysorbate, 7.2 mg of sodium dihydrogen phosphate, 1.8 mg of disodium hydrogen phosphate, 8.9 mg of benzyl alcohol and the balance of water; compared with the traditional methylprednisolone acetate injection, the methylprednisolone acetate injection provided by the invention has the advantages that the solubility is improved, the preparation stability is high, the absorption capacity of people on the methylprednisolone acetate injection can be improved, the methylprednisolone acetate injection can be applied to intravenous injection, and the application range of the methylprednisolone acetate injection is widened.

The present invention provides stable formulations including a fusion protein including an interleukin-12 (IL-12) and an antibody. The stable formulations include a citrate buffer, an arginine stabilizer, a sugar, that is sucrose, and polysorbate 20 (PS20) as a surfactant. Also provided herein are pharmaceutical combinations including said stable formulations and one or more agents including anticancer agents, such as immune checkpoint inhibitors and / or immune modulators, such as peptides administered along with an immunogenic enhancer, such as a cationic lipid. Further, provided herein are methods of use of said formulations and combinations for treating cancer.

This invention relates to the field of pharmaceutical formulation technology, specifically to an inhaled ipratropium bromide solution and its preparation method. The inhaled ipratropium bromide solution of this invention is prepared by dissolving sodium chloride in water for injection, adjusting the pH to 3.1-3.5 using a citrate-sodium citrate buffer system, adding a composite surfactant, and finally adding ipratropium bromide. The mixture is stirred to dissolve, diluted to volume, filtered, and sterilized. The composite surfactant is a mixture of polysorbate 20, polysorbate 60, and polysorbate 80. The inhaled ipratropium bromide solution of this invention exhibits excellent stability, can be stored for extended periods without deterioration, and has superior nebulization performance, meeting the needs of various patients.

Provided are a moist-heat sterilized nimodipine composition free of ethanol and phospholipid and a method for preparing the same. The composition comprises (1) nimodipine; (2) a non-phospholipid surfactant selected from polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, polyoxyl 15 hydroxystearate, D-alpha-tocopherol polyethylene glycol 1000 succinate (TPGS), polysorbates, glyceryl monocaprylocaprate, or any mixture of two or more thereof; and (3) a co-solvent, which is propylene glycol.

This invention relates to the field of ophthalmic formulation technology, specifically disclosing a long-lasting moisturizing contact lens lubricant and its preparation method. The lubricant comprises an oil phase component consisting of active liquid paraffin, a ceramide analog, and phytosterol polyoxyethylene ether-20; an aqueous phase component consisting of an osmotic pressure regulator and purified water; and a cationic agent and a composite surfactant dispersed at the interface. The composite surfactant is composed of polysorbate 80 and sucrose stearate, and the dosage form is an oil-in-water nanoemulsion. Its preparation involves phase preparation, emulsification homogenization and interface control, stabilization treatment, and aseptic molding steps. The product exhibits good ocular compatibility, long-lasting moisturizing properties, and a stable emulsion system, significantly improving the comfort of contact lens wear.